Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC (HKMPF) Stock Overview
Explore Hikma Pharmaceuticals PLC’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
4.2B
P/E Ratio
11.43
EPS (TTM)
$1.67
ROE
0.15%
HKMPF Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Hikma Pharmaceuticals PLC (HKMPF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 33.17, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $21.23.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 11.43 and a market capitalization of 4.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.